𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimal apheresis treatment volume for the efficacy and safety of leukocytapheresis with cellsorba in patients with active ulcerative colitis

✍ Scribed by Ken Fukunaga; Koji Kamikozuru; Yoko Yokoyama; Nobuyuki Hida; Yoshio Ohda; Naohisa Takeda; Koji Yoshida; Masaki Iimuro; Risa Kikuyama; Kyoichi Kato; Kazuko Nagase; Shiro Nakamura; Hiroto Miwa; Takayuki Matsumoto


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
165 KB
Volume
26
Category
Article
ISSN
0733-2459

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background: Leukocytapheresis (LCAP) is used as an adjunct therapy for patients with active ulcerative colitis (UC). Although, LCAP is routinely performed at 3,000 mL per session, we were interested to see that if this can be replaced with bodyweight (BW) adjusted volume. Methods: In an open label prospective trial, the clinical response to BW adjusted LCAP (BWA‐LCAP) was evaluated in 14 patients with active UC. Fourteen demography matched UC patients who had been treated with the routine 3,000 mL LCAP were randomly sampled from our database as a control group. All patients were given 10 weekly LCAP sessions. In the BWA‐LCAP group, the processed blood volume (PBV) was set at 30 mL/kg × BW/session. Baseline demographic measures were not significantly different between the two groups. Results: The average PBV in the BWA‐LCAP group was 1971.0 ± 330.0 mL, range 1,020–2,460. In both groups, the average UC clinical disease activity index, the endoscopic index, and the concomitant prednisolone dosage were significantly and equally reduced during the course of 10 LCAP. Accordingly, at the end of the trial, no significant difference was seen in any outcome measure between the two groups. However, a significantly higher incidence of adverse event (AE) was observed in the routine 3,000 mL LCAP group as compared with the BWA‐LCAP group (P < 0.01). Conclusions: The outcomes of this investigation showed that the therapeutic efficacy of LCAP based on 30 mL/kg × BW is similar to the routine 3,000 mL per session LCAP. However, BWA‐LCAP should be favored if one is to see the full potential of LCAP without AE. © 2011 Wiley Periodicals, Inc.


📜 SIMILAR VOLUMES


Safety and tolerability of a modified fi
✍ Vladislaw Muratov; Joachim Lundahl; Aleksandra Mandic-Havelka; Kerstin Elvin; Åk 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract Cellsorba™ is a medical device for leukocytapheresis (LCAP) treatment of ulcerative colitis (UC). Cellsorba™ EX Global type has been developed from Cellsorba E for intended use with ACD‐A as anticoagulant. We evaluated safety and efficacy of the modified Cellsorba using ACD‐A in a pilot

Safety and efficacy of a multicenter stu
✍ Nancy D. Doolittle; Michael E. Miner; Walter A. Hall; Tali Siegal; E. Jerome Han 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 309 KB 👁 2 views

The aim of this study was to determine the safety and efficacy of intraarterial chemotherapy with osmotic opening of the blood-brain barrier (BBB) for the treatment of malignant brain tumors when administered across multiple centers.

Comparison of the efficacy and safety of
✍ Rene-Jean Bensadoun; Jamel Daoud; Brahim El Gueddari; Laurent Bastit; Rene Gourm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 2 views

## Abstract ## BACKGROUND. Topical antifungal treatments are recommended but rarely used as first‐line therapy for oropharyngeal candidiasis (OPC) in patients with cancer. Miconazole Lauriad 50‐mg mucoadhesive buccal tablet (MBT) Loramyc reportedly delivered rapid and prolonged, effective concentr